for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

旭化成株式会社

3407.T

現在値

956.40JPY

変化

0.90(+0.09%)

出来高

3,059,800

本日のレンジ

950.50

 - 

964.80

52週レンジ

946.60

 - 

1,238.50

∙ 約20分前の相場を表示しています。

適時開示

Asahi Kasei's Fiscal 2021 Group Operating Profit Grew About 20% To Roughly 200 Bln Yen - Nikkei

May 6 (Reuters) - Nikkei::ASAHI KASEI'S GROUP OPERATING PROFIT GREW ABOUT 20% TO ROUGHLY 200 BILLION YEN IN FISCAL 2021 - NIKKEI.ASAHI KASEI'S SALES ROSE ABOUT 20% TO 2.45 TRILLION YEN IN FISCAL 2021 - NIKKEI.

Asahi Kasei to Start Providing Carbon Footprint Data for Each Product of Performance Resins

April 27 (Reuters) - Asahi Kasei Corp <3407.T>::ASAHI KASEI TO START PROVIDING CARBON FOOTPRINT DATA FOR EACH PRODUCT OF PERFORMANCE RESINS.ASAHI KASEI CORP- ESTABLISHED PLATFORM JOINTLY WITH NTT DATA CORP. TO GRASP AMOUNT OF GHG EMISSIONS AND CFP FOR EACH GRADE OF PERFORMANCE PLASTICS.ASAHI KASEI CORP- USE OF PLATFORM BEGAN IN APRIL 2022, AND CFP DATA PROVISION TO CUSTOMERS WILL BEGIN IN MAY 2022.

Basilea's Partner Asahi Kasei Pharma Files New Drug Application In Japan

Sept 30 (Reuters) - BASILEA PHARMACEUTICALS <BSLN.S>::BASILEA'S PARTNER ASAHI KASEI PHARMA FILED NEW DRUG APPLICATION FOR MARKETING AUTHORIZATION OF ISAVUCONAZOLE IN JAPAN.BASILEA PHARMACEUTICA AG - FILING TRIGGERS A CHF 5 MILLION MILESTONE PAYMENT FROM ASAHI KASEI PHARMA TO BASILEA.

Basilea's Partner Asahi Kasei Files For Isavuconazole Authorization In Japan

July 26 (Reuters) - BASILEA PHARMACEUTICA AG <BSLN.S>::BASILEA’S PARTNER ASAHI KASEI PHARMA PREPARES NDA FILING FOR THE MARKETING AUTHORIZATION OF ISAVUCONAZOLE IN JAPAN BASED ON POSITIVE PHASE 3 STUDY RESULTS.

Lilly And Asahi Kasei Pharma Announce License Agreement For Chronic Pain Drug Candidate

Jan 28 (Reuters) - Asahi Kasei Corp <3407.T>::LILLY AND ASAHI KASEI PHARMA ANNOUNCE LICENSE AGREEMENT FOR CHRONIC PAIN DRUG CANDIDATE.ELI LILLY AND CO - UNDER TERMS OF AGREEMENT, LILLY WILL BE RESPONSIBLE FOR FUTURE GLOBAL DEVELOPMENT AND REGULATORY ACTIVITIES FOR AK1780.ELI LILLY AND CO - TRANSACTION WILL BE REFLECTED IN LILLY'S REPORTED RESULTS AND FINANCIAL GUIDANCE ACCORDING TO GAAP.ELI LILLY AND CO - LILLY WILL PAY ASAHI KASEI PHARMA AN UPFRONT PAYMENT OF $20 MILLION.ELI LILLY AND CO - NO CHANGE TO LILLY'S 2021 NON-GAAP EARNINGS PER SHARE GUIDANCE AS RESULT OF THIS DEAL.ELI LILLY AND CO - ASAHI KASEI PHARMA MAY BE ELIGIBLE FOR UP TO $210 MILLION IN POTENTIAL DEVELOPMENT AND REGULATORY MILESTONES.ELI LILLY AND CO - ASAHI KASEI PHARMA WILL RETAIN RIGHT TO PROMOTE AK1780 IN JAPAN AND CHINA.ELI LILLY AND CO - IF AK1780 IS SUCCESSFULLY COMMERCIALIZED, ASAHI KASEI PHARMA WOULD BE ELIGIBLE FOR UP TO $180 MILLION IN POTENTIAL SALES MILESTONES.

Adient Enters Into Agreement To Sell Its Fabrics Business For $175 Mln

March 5 (Reuters) - Adient Plc <ADNT.N>::PRESS RELEASE - ADIENT ENTERS INTO AGREEMENT TO SELL ITS FABRICS BUSINESS.AGREEMENT TO SELL ITS AUTOMOTIVE FABRICS MANUFACTURING BUSINESS, INCLUDING ITS LAMINATION BUSINESS, TO SAGE AUTOMOTIVE INTERIORS FOR $175M.PENDING SALE INCLUDES 11 FACILITIES GLOBALLY, WITH MAJORITY LOCATED IN EUROPE, WITH APPROXIMATELY 1,300 EMPLOYEES.

Veloxis: Asahi Kasei Pharma Denmark Announces Preliminary Result Of Its Public Tender Offer For Shares And Warrants In Co

Jan 15 (Reuters) - Veloxis Pharmaceuticals A/S <VELOX.CO>::REG-VELOXIS PHARMACEUTICALS: ASAHI KASEI PHARMA DENMARK ANNOUNCES THE PRELIMINARY RESULT AND COMPLETION OF ITS PUBLIC TENDER OFFER FOR THE SHARES AND WARRANTS IN VELOXIS PHARMACEUTICALS.PRELIMINARY AND NON-BINDING COUNTING OF ACCEPTANCES SHOWS THAT ASAHI KASEI PHARMA DENMARK HAS RECEIVED VALID ACCEPTANCES OF RECOMMENDED CONDITIONAL VOLUNTARY PUBLIC OFFER TO SHAREHOLDERS AND WARRANTHOLDERS OF VELOXIS FOR A TOTAL OF 88.48% OF SHARE CAPITAL AND VOTING RIGHTS ON A FULLY DILUTED BASIS.IN ADDITION TO TENDERED SHARES AND WARRANTS, ASAHI KASEI CORPORATION OWNS 37,828,149 SHARES WHICH WILL BE SOLD TO ASAHI KASEI PHARMA DENMARK WHEREBY ASAHI KASEI PHARMA DENMARK WILL HOLD A TOTAL OF 90.44% OF TOTAL SHARE CAPITAL AND VOTING RIGHTS ON A FULLY DILUTED BASIS.

Competition Approvals Obtained For Asahi Kasei Pharma Denmark Offer For Veloxis Pharmaceuticals

Jan 9 (Reuters) - Veloxis Pharmaceuticals A/S <VELOX.CO>::REG-VELOXIS PHARMACEUTICALS: COMPETITION APPROVALS OBTAINED FOR THE PUBLIC TENDER OFFER BY ASAHI KASEI PHARMA DENMARK FOR THE SHARES AND WARRANTS IN VELOXIS PHARMACEUTICALS.ALL CONDITIONS OF OFFER ARE EXPECTED TO BE SATISFIED UPON OR PRIOR TO EXPIRY OF OFFER PERIOD.

Zoll Signs Definitive Agreement To Purchase Cardiac Science

June 11 (Reuters) - Asahi Kasei Corp <3407.T>::ZOLL SIGNS DEFINITIVE AGREEMENT TO PURCHASE CARDIAC SCIENCE.ASAHI KASEI CORP - TO PURCHASE CARDIAC SCIENCE CORPORATION FROM AURORA RESURGENCE.ASAHI KASEI CORP - ADDITIONAL TERMS OF AGREEMENT ARE NOT BEING DISCLOSED.

Asahi Kasei To Cancel 8,684,300 Treasury Shares Oct 11

May 31 (Reuters) - Asahi Kasei Corp <3407.T>::TO CANCEL 8,684,300 TREASURY SHARES OCT 11.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up